This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Repros CEO: My Testosterone Drug Helped Gay Cubans Have Lots of Sex

Repros says Androxal achieved both primary endpoints in the study with statistical significance. However, the company left a lot of data undisclosed and questions about the conduct of the study unanswered.

On the testosterone endpoint, Repros says 79% of the intent-to-treat, Androxal-treated men exhibited 24-hour testosterone levels that were in the normal range after 12 weeks, therefore exceeding the 75% threshold.

Repros did not disclose the mean or median testosterone levels for the men treated with Androxal in the study, nor did the company say anything about how the men treated with placebo performed with respect to testosterone levels.

In a separate "completers" analysis, 83% of men treated with Androxal had a mean 24-hour testosterone of 425 ng/dl, Repros said. [The "normal" testosterone range was defined at 300-1040 ng/dl.]

If Repros had mean testosterone levels for the "completers" in the study, the company surely has similar data on the more-important intent-to-treat patients, yet this information was not disclosed. [And none of the analysts on the conference call bothered to ask.]

Repros provided even less disclosure for the sperm count endpoint, while acknowledging that the conduct of this portion of the study ran into problems. Repros claims that Androxal-treated men with "valid baseline sperm results" had sperm counts 12 weeks later that were non-inferior to placebo patients -- good enough to claim victory.

On the conference call, Podolski said 15 men on Androxal had sperm counts that fell below 50% of baseline compared to 1 man treated with placebo. Repros also acknowledged that if the largest-enrolling clinical trial site was removed from the analysis, the sperm-count endpoint failed to reach statistical significance. FDA will examine the sperm count data with and without the data from this clinical trial site, Podolski said.

This is also where we get back to the gay Cubans. Podolksi argued that some of the low sperm counts recorded in the study were the result of men having too much sex, and not due to Androxal. He also tried to downplay any negative effect resulting from another clinical trial site where baseline sperm counts were made up or missing.

A second phase III study of Androxal is underway, with enrollment expect to wrap in May. Podolski insists the data announced Thursday should convince investors that the second study will also be positive.

But what about all the inconsistencies in the clinical trial and and missing Androxal data?

"I think FDA will be just fine with these results," Podolski said.

And why should investors trust Podolski?

"If you're in my kitchen, you may not like the way the food smells, but hopefully, it tastes good," he said.

I have no idea what that means, either.

-- Reported by Adam Feuerstein in Boston.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.
2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AUXL $36.47 -0.16%
ABBV $61.13 0.00%
LLY $83.88 0.00%
RPRX $1.78 0.00%
AAPL $118.88 0.00%


Chart of I:DJI
DOW 17,812.19 +19.51 0.11%
S&P 500 2,089.14 +2.55 0.12%
NASDAQ 5,102.8080 +0.33 0.01%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs